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Objectives: Many patients with aortic aneurysms have renal insufficiency and may be at increased risk when conventional
imaging modalities (contrast-enhanced computed tomography and arteriography) are used for aortic endograft design.
Our objective was to determine if magnetic resonance angiography (MRA) could be used as the sole imaging modality
for endoprosthetic design.
Methods: A total of 96 consecutive patients who underwent endovascular repair of thoracic (5) and abdominal (91) aor-
tic aneurysms (April 1998–December 1999) were included in this study. Data were collected prospectively. Gadolinium-
enhanced MRA was used preoperatively in place of conventional imaging if renal insufficiency or a history of severe
contrast reaction was present. The control group underwent conventional imaging. Endografts used included Ancure,
AneuRx, and Talent.
Results: Fourteen patients (14.6%) had their endografts designed solely with MRA. Intraoperative access failure; prox-
imal and distal extensions (unplanned); conversion to open, aborted procedures; and endoleaks occurred with equal
frequency in both the MRA-designed and control groups (16.7% vs 18.3%, respectively; P = .33). Despite baseline renal
insufficiency, there was no significant rise in the creatinine level after endograft implantation in patients with an MRA
design (preoperative level, 1.8; postoperative level, 1.9; P = .5).
Conclusion: MRA may be successfully used as the sole modality for aortic endograft design. The use of MRA for this
purpose is noninvasive and minimizes nephrotoxic risk. (J Vasc Surg 2001;33:488-94.)
depends as much on precise preoperative measurement and
endograft design as on intraoperative technique. Therefore,
accurate preoperative imaging is essential. The most com-
monly used modalities are the combination of unenhanced
and intravenous contrast-enhanced computed tomography
(CT) of the abdomen and pelvis with 3-mm cuts and bipla-
nar aortography performed with a radiopaque marker
catheter. These studies allow the assessment of iliac tortuos-
ity and calcification and allow accurate measurement of the
diameter and lengths of endografts required for successful
exclusion of the aneurysm. 
Unfortunately, a significant number of patients are
unable to safely undergo these procedures because of
either renal insufficiency or an allergy to the contrast dye.
The incidence of contrast-related nephropathy in patients
with baseline renal insufficiency can range from 9% to
93%, depending on the contrast agent used, underlying
comorbidities, volume, and preprocedure preparation.2
Magnetic resonance angiography (MRA) is performed
to obtain images without the use of ionizing radiation or
contrast dye. Gadolinium-enhanced delayed images allow
visualization of both the flow lumen and the aneurysmal
(adventitial) wall and allow visualization of all major
branches in multiple projections, allowing endograft
design with a workstation. 
The purpose of this study was to compare the early out-
come of aortic endografts designed solely with the use of
MRA with regard to intraoperative access failure, unplanned
use of proximal and distal extensions, conversion to an open
procedure, aborted procedures, and the incidence of
endoleaks. Additionally, radiation time, radiation dose, and
procedure time were compared. These parameters were
Endograft repair of an abdominal aortic aneurysm
(AAA) was first reported by Parodi et al in 1991.1 Since that
time, aortic endografting has become widespread and may
even be considered the current standard of care for the repair
of AAAs in patients with significant medical comorbidities,
which would make open repair risky. The development and
proliferation of aortic endograft devices have certainly been
enhanced by the involvement of industry. Currently, there
are a large variety of endograft devices that are in varying
stages of clinical trials. To date, only the Ancure (Guidant-
Endovascular Technologies [EVT], Menlo Park, Calif) and
AneuRx (Medtronics, Santa Rosa, Calif) possess conditional
Food and Drug Administration approval.
In the current study we used the previously named
devices and a significant number of Talent (World Medical-
Medtronics, Sunrise, Calif) devices, which, like the AneuRx
devices, are modular and fully supported with nitinol
stents. Additionally, a row of proximal bare springs allows
suprarenal fixation while preserving flow to the kidneys. 
The success or failure of an aortic endograft procedure
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compared with those in a control group whose endografts
were designed with conventional modalities.
METHODS
A total of 96 consecutive patients who underwent
endovascular repair of thoracic (5) and abdominal (91)
aortic aneurysms were included in this study. This study
met with approval by our institutional review board and
human ethics committee. The repairs were performed
between April 1998 and December 1999 and included all
aortic endograft procedures performed during this period.
All data were collected prospectively and reviewed retro-
spectively. Gadolinium-enhanced MRA was used preoper-
atively in place of conventional imaging if renal
insufficiency or a history of severe contrast reaction was
present. For the purposes of this study, renal insufficiency
was defined as the patient having a creatinine level of more
than 1.5 mg/dL before imaging. There were no patients
undergoing dialysis. No patients in the MRA group
received any preoperative contrast-enhanced study at
either our institution or an outside institution. The only
screening studies used were unenhanced CT or ultrasound
scan. The control group underwent conventional imag-
ing, which included unenhanced and intravenous contrast-
enhanced CT of the abdomen and pelvis with 3-mm cuts,
as well as biplanar aortography with a radiopaque marker
catheter. There was no crossover between groups. A single
vascular surgeon (R.F.) designed all endografts. 
MRA was performed on a 1.5 Tesla system (Signa,
General Electric Medical Systems, Milwaukee, Wis).
Coronal single shot fast spin echo localizers followed by
axial single shot fast spin echo sequences, followed by
sagittal type 3 Dearing strain dynamic gadolinium
enhancement with 30 cc of contrast and postcontrast axial
sequences. 
CT imaging of the abdomen and pelvis was per-
formed. After acquisition of initial unenhanced localizing
images with 10-mm cuts, a test dose injection with 16 cc
of nonionic contrast material at a rate of 4 cc/s was used
to demonstrate a circulation time. Subsequently, a CT
angiography (CTA) study was performed with 100 cc of
nonionic contrast material injected at 4 cc/s with a scan
delay depending on the calculated circulation time. A 3-
mm slice collimation was used from the celiac artery to the
proximal femoral vessels.
A transfemoral aortogram was performed with a
marker catheter in the aorta and pelvis. Anteroposterior
and lateral views of the aorta were obtained with the
catheter positioned at the level of the renal arteries, as
well as anteroposterior and right and left anterior
oblique views of the pelvic vessels with an aortic bifurca-
tion injection.
Early outcome parameters of all procedures were ana-
lyzed by determination of the following end points: intra-
operative access failure, unplanned use of proximal or distal
extensions, conversion to an open procedure, aborted pro-
cedures, and the incidence of any endoleak. Additionally,
total radiation time, radiation dose, and procedure length
were noted. Preoperative and postoperative creatinine lev-
els of all patients were routinely obtained. Statistical analy-
sis included the Fisher exact test and χ2 testing. 
Fig 1. Gadolinium-enhanced MRA of an AAA with descending
thoracic dissection. Note dissection continuing into left common
iliac artery. A single right renal artery and two left renal arteries
are demonstrated. Main left renal artery is fed partially by false
lumen of dissection. 
Fig 2. A 2-D time of flight MRA of patient in Fig 1. Aneurysm
is successfully excluded with preservation of all renal arteries.
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RESULTS
Fourteen patients (14.6%) had their endografts
designed solely with MRA (Figs 1-5). The reasons for
choosing MRA were renal insufficiency in 12 patients and a
history of severe contrast dye reaction refractory to peripro-
cedural steroid and antihistamine preparation in two
patients. None of the procedures with MRA-designed
endografts resulted in failure to obtain access or needed to
be aborted. Three of the 82 control procedures with con-
ventional imaging design had to be aborted because of fail-
ure to obtain access. This was not statistically significant.
There were no conversions to an open procedure in either
group. 
Nine (11%) of 82 control procedures had an intraoper-
ative proximal leak after placement of the main graft body,
whereas there were none in the MRA group. These were
all immediately and successfully addressed with proximal
covered extensions. This was not statistically significant.
Two additional patients in the control group required the
use of an unplanned proximal extension, although they did
not demonstrate a proximal endoleak. No proximal exten-
sions were needed in the MRA group. This was not statis-
tically significant. 
With regard to distal endoleaks and extensions, there
were three (21%) of 14 distal endoleaks noted during the
procedure in the MRA group and 12 (14%) of 82 distal
endoleaks in the control group (not statistically signifi-
cant). All distal endoleaks were immediately and success-
fully resolved with distal covered extensions. 
There were five (36%) cases requiring the use of
unplanned distal extensions in the MRA group as com-
pared with 41 (50%) cases in the control group (not sta-
tistically significant). There were no instances of junctional
or graft material endoleak in the MRA group, and only
three (3.7%) instances of a junctional or graft leak in the
control group (not statistically significant).
All grafts were studied within 30 days for evidence of
endoleak. Contrast-enhanced CT was used for postoperative
imaging in the control group and MRA in the study group.
All postoperative studies used delayed contrast imaging to
maximize sensitivity in detecting even slow endoleaks. There
was a 16.7% incidence of postoperative (30-day) endoleak in
the MRA group and an 18.3% incidence in the control
group. Most of these were the type II variety. However,
there were two proximal endoleaks present at 30 days post-
operatively in the control group and one distal attachment
site endoleak in the control group. All 30-day endoleaks
were studied with angiography and definitively diagnosed
(Figs 6 and 7).
The total procedure time for the MRA-design group
and the control group was 2.33 hours and 2.8 hours,
respectively, (not statistically significant). The volume of
contrast used was 154 mL in the control group as com-
pared with 95 mL in the MRA-design group (P = .058).
Total intraoperative fluoroscopy time was 42 minutes in
the MRA-design group and 36 minutes in the control
group (not statistically significant). The radiation dose was
7249 rad/cm2 in the MRA group as compared with 6595
rad/cm2 in the control group (not statistically significant).
The mean preoperative creatinine level in the MRA-
design group was 1.8 mg/dL, whereas in the control
group it was 1.4 mg/dL. This did not meet with statisti-
cal significance. Fortunately, the postoperative creatinine
levels in both groups did not vary significantly from pre-
Fig 3. Gadolinium-enhanced MRA of saccular thoracic aortic
aneurysm.
Fig 4. Status of patient in Fig 3 after stent graft repair. Note lim-
itation of MRA to demonstrate lumen within a stented graft. 
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operative levels (1.98 mg/dL for the MRA group and 1.4
mg/dL for the control group). 
DISCUSSION
This study demonstrates the feasibility of using MRA
as the sole preoperative imaging modality before aortic
endografting. When compared with a control group with
conventional CT and marker catheter aortography, there
was no difference in the incidence of conversion to open
procedures, aborted procedures, or ability to obtain access
for placement of the device. Additionally, there was no
increase in the incidence of unplanned proximal or distal
extensions or overall endoleak rate. Admittedly, because
most endoleaks were of the type II variety, it would be
unlikely for this number to be influenced by the imaging
modality chosen to design the endograft. With respect to
type I endoleaks, there was also no significant difference
between the groups. A potential for bias exists here
because clearly, in an effort to minimize the use of contrast
material in patients with renal insufficiency, the technique
of completion arteriography may have differed between
the groups. Although all proximal completion arterio-
grams were performed with a pigtail catheter and power
injector, there may have been differences in volume, type,
and concentration of contrast material between the two
groups. It would be expected, however, that any missed
type I endoleaks would become manifest on follow-up
imaging designed to be sensitive to even slow leaks. Also,
there was no significant difference between MRA-
designed procedures and control procedures with regard
to fluoroscopy time, radiation dose, and overall operative
procedure time.
A primary motivator for this study was to minimize
the use of nephrotoxic agents in the performance of aor-
tic endografting of patients with renal insufficiency. In a
recent large, prospective, randomized, trial of almost 1200
patients undergoing cardiac catheterization, the incidence
of renal dysfunction was 7% in patients receiving an ionic
agent and 3% in patients receiving a nonionic contrast
agent.3 All patients in this study underwent periprocedural
hydration. Renal dysfunction was defined as an increase in
the serum creatinine level of 1 mg/dL or more 48 to 72
hours after contrast. Baseline renal insufficiency was an
independent risk factor for developing contrast-induced
nephropathy. The incidence of clinically severe adverse
events was 1.25%.3 In another recent study of patients
with baseline renal insufficiency receiving radiocontrast
agents, 11% to 40% of patients experienced nephrotoxicity
Fig 5. Delayed sequence gadolinium-enhanced MRA demon-
strating value of visualizing true dimensions of aneurysm. This is
patient’s status after stent graft repair. No endoleak is observed. 
Fig 6. A 2-D time of flight MRA demonstrating large endoleak
of uncertain etiology.
Fig 7. Gadolinium-based contrast arteriogram of patient in Fig 6.
This study identifies endoleak resulting from high-riding, patent
inferior mesenteric artery that was successfully coil embolized. 
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as evidenced by an increase in the serum creatinine level of
0.5 mg/dL 48 hours after injection.4 Even the use of
small amounts of nonionic contrast material to enhance
carbon dioxide or gadodiamide contrast studies resulted in
a worsening of renal function at 48 hours. Despite mini-
mal contrast use, the mean creatinine level in the MRA
group rose from 1.8 mg/dL preoperatively to 1.98
mg/dL postoperatively. Although this was not statistically
significant, it does represent a concerning trend, suggest-
ing that reducing contrast load wherever possible would
be desirable. The incidence of a relevant systemic reaction
to contrast material is approximately 5% with a small per-
centage of these being severe.5 The incidence of a severe
reaction is, however, increased in patients with a history of
a prior reaction or allergies in general.6
Overall, gadolinium has been proved to be quite safe.
In a study of 21,000 patients who underwent gadolinium-
enhanced MR studies at the University of Michigan, there
were only 36 adverse reactions. Of these, two (0.01%) were
considered severe, anaphylactoid reactions. The authors
note, however, that this is higher than the reported rate of
anaphylactoid reactions reported in the literature.7
In a retrospective study of more than 15,000 patients
who underwent gadolinium-enhanced magnetic reso-
nance imaging (MRI) examinations, Arsenault et al8
focused on 151 patients who had a serum creatinine level
of more than 2 mg/dL. The overall incidence of adverse
events was 3.6% with no severe or life-threatening reac-
tions. The authors note this was not dissimilar to the per-
centage of adverse reactions in patients with normal renal
function. There was no real change in creatinine levels
after the procedure, with mean serum creatinine levels of
2.5 mg/dL and 2.3 mg/dL before and after the proce-
dure, respectively.
Prince et al9 studied the effects of high-dose gadolin-
ium (0.2 to 0.4 mmol/kg) on renal function. They com-
pared preprocedure and postprocedure serum creatinine
levels of patients who underwent both gadolinium-
enhanced MR and an iodinated contrast study. The mean
change in serum creatinine levels after gadolinium-
enhanced MR was 0.7 mg/dL. The mean change in cre-
atinine levels after iodinated contrast was +0.35 mg/dL.
The authors note that none of the patients experienced
gadolinium-induced renal failure despite the high dose and
high prevalence of renal insufficiency. Although these stud-
ies demonstrate that the use of gadolinium is less nephro-
toxic than iodinated contrast, it should not be inferred that
an individual patient is completely free of nephrotoxic risk
when undergoing a gadolinium-enhanced study. 
MRA imaging techniques used in this study are not those
of standard MRA. Standard MRA with two-dimensional 
(2-D) time of flight only provides imaging that is based on
moving particles, and therefore, only demonstrates the flow
lumen. In this regard, it has the same limitations of standard
angiography in the inability to demonstrate the true aneurysm
dimensions. The techniques used in this study required the use
of gadolinium-enhanced delayed images, which provided visu-
alization of the flow lumen and the external dimensions of the
aneurysm similar to contrast-enhanced CT. This is based on
the dynamic acquisition of a heavily T1-weighted gradient-
echo pulse sequence during the injection of a gadolinium con-
trast agent. The gadolinium causes a dramatic shortening of
the T1 in the vascular tree, thereby creating a high level of
contrast with background tissue.
MRA allows the acquisition of true three-dimensional
(3-D) data, in contrast to conventional angiography in
which only 2-D projection data may be obtained. As such,
MRA images may be more revealing in cases of complex,
tortuous arterial anatomy. The 3-D capability is also
exploited to make accurate measurements for stent graft
repair (Fig 8). Additionally, MRA provides higher back-
ground suppression than CTA, in which structures such as
Fig 8. Gadolinium-enhanced MRA demonstrating ability to view vascular structures from all angles to best under-
stand relative anatomy and tortuosity at computer workstation. 
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bone and calcification may interfere with the creation of
maximum intensity pixel images.
MRA examinations typically have relatively short
acquisition times. Although an integrated MRI/MRA
examination requires approximately 1 hour to perform,
the MRA data themselves only require approximately 5
minutes to acquire. Therefore, a “focused” MRA exami-
nation may be easily completed in less than half an hour.
MRA provides higher background suppression than
CTA. In CTA, structures such as bone and calcification
may interfere with the creation of maximum intensity pixel
images.
The accurate interpretation necessary to obtain ade-
quate diameter and length measurements requires exami-
nation of the images at a computer-driven workstation
with the appropriate software and the assistance of an MR
radiologist with an interest in MRA. Such equipment and
experience may not yet be available at all institutions. 
As expected, there are some limitations to using MRA
as the sole preoperative imaging modality. For instance,
MRA does not obviate the need for real-time imaging dur-
ing the procedure itself. In certain instances, however, we
have been able to use gadolinium-enhanced fluoroscopy to
limit or eliminate the use of standard contrast material dur-
ing endograft placement. There are a number of people
who cannot undergo an MRI. These include patients with
certain metallic implants, pacemakers, and metal in the eye
due to trauma. Additionally, a number of people are too
claustrophobic to tolerate an MR examination or are unable
to maintain a breath hold for the required duration. MRA
is susceptible to a variety of artifacts, including artifacts 
from cardiac/respiratory motion, metallic objects, and air-
containing structures. MRA cannot depict the lumen of an
intravascular stent. The MRA images are also limited by
intravascular coils. This is particularly pertinent because a
number of patients undergo preoperative embolization of
the hypogastric artery if exclusion of an iliac artery
aneurysm is planned. In the past, MRA has been considered
lacking, in that accessory renal arteries may be missed and
3-D performance is inferior.10 In our experience accessory
renal arteries are easily observed on MRA images.
It remains unclear whether patients whose aortic
endografts possess a stainless steel framework can safely
undergo MRA imaging. It appears that nitinol-supported
grafts can be imaged with MRA without difficulty. There
is perhaps some theoretical concern for imaging endolu-
minally placed stent grafts with MRA because heating of
the metallic stent may be problematic. Hilfiker et al11
studied nitinol-based stent grafts in vitro to assess heating
and imaging characteristics. The authors report no tem-
perature changes associated with the stent during scan-
ning. Additionally, the hooks on the Guidant graft do not
appear to be problematic with respect to MRA imaging
quality in our experience. 
Patients who underwent MRA imaging for endograft
design were followed up with MRA. There did not seem
to be any difficulty picking up endoleaks with MRA; how-
ever, this was not formally studied by having concurrent
CT angiograms. All endoleaks, however, were further
studied with angiography for definitive diagnosis and for
attempted repair. The use of MRA for the follow-up of
patients who received an aortic endograft has been
reported.12 In their study, Engellau et al12 evaluated 15
consecutive patients who received nitinol-based stent
grafts for treatment of an AAA. The authors report that
MRA provided the relevant information needed for fol-
low-up of endoluminally treated AAAs and was particu-
larly useful in evaluating periaortic inflammation,
thrombus reorganization, and vertebral body infarction. 
Clearly, not all studies may be needed in all patients.
The rigidity used currently in obtaining both a CT
angiogram and a marker catheter aortogram is largely to
satisfy study protocols and Food and Drug Administration
guidelines. Most, if not all, length and diameter measure-
ments can be taken from the cross-sectional imaging.
Currently, angiography is useful in that CTA shows
stenoses poorly, and if a vessel is particularly tortuous, the
length measurements obtained with CTA may be artifi-
cially shortened. In the future, it is likely that the studies
selected will be more individualized depending on comor-
bidities, physical examination, and vascular anatomy. 
In this study, patients underwent MRA imaging
because of a relative contraindication to studies requiring
iodinated contrast agents. For this reason, there is no
direct comparison between MRA and CTA with regard to
actual measurements. It is possible, therefore, that patients
who were rejected by MRA may have been candidates if
measured with CTA and angiography. Thurnher et al,13 at
the University of Vienna, compared 61 patients with
AAAs who underwent gadolinium-enhanced MRA, CTA,
and digital subtraction angiography. The authors report
that MRA and CTA were equivalent with respect to eval-
uating the proximal extent of the aneurysm and all aortic
dimensions. MRA was superior in assessing iliac vessel dis-
ease in their study because of a larger field of view. They
found MRA to be inferior in the depiction of accessory
renal arteries and in the accuracy of grading renal artery
stenoses. Other authors have reported favorable results
with MRA to measure the dimensions required for suc-
cessful aortic endograft placement as well.14,15
Unfortunately, MRA does not adequately demon-
strate the extent of arterial calcification. It is particularly
important to know the extent of iliac artery calcification
because this bears on one’s ability to achieve access to the
aortic aneurysm via the femoral route. A highly calcified
iliac artery or aortic bifurcation may not safely permit
advancement of the device, and this would be important
to know preoperatively. Therefore, we recommend obtain-
ing nonenhanced CT imaging of the abdomen and pelvis
in addition to MRA because this would not involve the use
of contrast material and the additional ionizing radiation is
negligible. It is possible that the combination of nonen-
hanced CT and MRA may become the procedure combi-
nation of choice in planning an endograft procedure. 
Clearly, this study was not designed to demonstrate
superiority of one preoperative imaging technique over
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another. It is likely that the small numbers, particularly in
the MRA group, may not allow for some true differences to
achieve statistical significance. However, we believe we have
demonstrated that the use of MRA as the sole preoperative
imaging modality can allow accurate endograft design. 
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